Back to search

Ireland· IE-PA-EU/1/17/1250/002

Rubraca 250 mg Film-coated tablet

A rucaparib product containing rucaparib camsylate, registered in Ireland by pharmaand GmbH.

ATC L01XX55

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedRubraca 250 mg Film-coated tabletATCL01XX55REGISTER NO.IE-PA-EU/1/17/1250/002PACKS LISTED1CHECKEDSeptember 28, 2026

The record

At a glance

HPRA (Ireland)
Active substance
Rucaparib camsylate
Manufacturer
pharmaand GmbH
Country
Ireland (IE)
ATC code
L01XX55
ATC class
Rucaparib
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1250/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

692 interactions on record for rucaparib.

Graded by severity as the source publishes them — 103 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rucaparib · interactions on record

692 records

  • 103 severe
  • 576 moderate
  • 13 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rucaparib in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rucaparib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ca1860ac-f902-47c6-9abf-a0eb79910cb2
GET /v1/drugs/ca1860ac-f902-47c6-9abf-a0eb79910cb2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XX",
    "L01XX55"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1250/002",
  "substances": [
    "Rucaparib camsylate"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "24/05/2018",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about rucaparib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.